| Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies | Frank Vinluan | 10/14/20 | Boston |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume | Frank Vinluan | 10/01/20 | Boston |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations | Sue Sutter | 09/22/20 | National |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Generate Bio Aims to Reveal Nature’s Protein Secrets, Create New Drugs | Frank Vinluan | 09/10/20 | Boston |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| Astellas Reports Third Patient Death in Audentes Gene Therapy Study | Frank Vinluan | 08/21/20 | San Francisco |
| FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data | Sarah de Crescenzo | 08/19/20 | National |
| FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy | Sarah de Crescenzo | 08/07/20 | National |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Delivery | Frank Vinluan | 07/22/20 | Boston |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding | Frank Vinluan | 07/21/20 | National |
| MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy | Sarah de Crescenzo | 07/17/20 | New York |
| Artiva Bio Raises $78M to Broaden Access to Cancer Cell Therapies | Sarah de Crescenzo | 06/26/20 | San Diego |
| CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy | Frank Vinluan | 06/25/20 | Philadelphia |
| FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products | Joanne S. Eglovitch | 06/25/20 | National |
| Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
| Timing Is an Essential Element of Cell & Gene Therapy Product Development | Sarah de Crescenzo | 06/19/20 | Philadelphia |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Sarepta Eyes Key Test for Gene Therapy in Rare Muscular Dystrophy | Sarah de Crescenzo | 06/08/20 | Boston |
| Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic | Frank Vinluan | 06/08/20 | Boston |
| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| Dyno Debuts With Plan, Partnerships for Better Gene Therapy Vectors | Sarah de Crescenzo | 05/11/20 | Boston |
